Important note

This AI stock analysis for Alnylam Pharmaceuticals is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Alnylam Pharmaceuticals - AI Stock Analysis

Analysis generated October 2, 2025

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. RNAi is a powerful biological process which selectively silences specific messenger RNAs (mRNAs) that encode disease-causing proteins. Alnylam's diverse pipeline targets a range of diseases, including genetic disorders, cancers, and liver diseases. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has grown to become a leader in innovative, RNA-based therapeutics.

Fundamental Analysis

The recent revenue for Alnylam Pharmaceuticals was $774 million for the last quarter, marking a 30.21% increase compared to the previous quarter and a 17.26% increase compared to the same quarter last year. This substantial growth in revenue is a strong sign of the company's ability to expand its market reach and product offerings.

Net income, however, presents a more complex picture. The company's net income for the last quarter was $66 million, representing a 15.31% decrease compared to the previous quarter and a staggering 292.43% decrease compared to the same quarter last year. These figures raise concerns about the company's profitability, despite its revenue growth.

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the last quarter was $19 million, reflecting a 64.40% increase compared to the previous quarter but a 49.23% decrease compared to the same quarter last year. Although there is positive momentum in the short term, the significant year-over-year decline is worrisome.

Moreover, recent insider selling of company stock could be interpreted as a bearish signal, suggesting that insiders might lack confidence in the company's near-term prospects.

Technical Analysis

Today's stock price stands at $451.45, representing a 1.00% increase compared to a month ago and a 67.50% increase compared to a year ago. These numbers highlight a positive short-term and long-term trend in stock performance.

However, the stock's technical indicators suggest a more bearish picture. The current Simple Moving Average (SMA10) is $451.72, lower than the previous SMA10 of $452.46, indicating a potential downward trend in price movement. Additionally, the Relative Strength Index (RSI) is 81.7, suggesting that the stock may be overbought and could face a price correction.

Alternative Data Analysis

Job postings and employee sentiment are important indicators of a company's growth and internal health. Alnylam Pharmaceuticals currently has 150 open positions, a 53% increase in the last couple of months, suggesting that the company is expanding and possibly gearing up for new projects or developments. However, the overall business outlook among employees remains neutral, indicating mixed sentiments internally.

Customer acquisition metrics also show a positive trend. The company has an estimated 64,000 visitors to their website, a 25% increase in the last couple of months, which can indicate an uptick in potential customers. Engagement on social media platforms is equally noteworthy. Alnylam has 2,200 Instagram followers, up by 9% in the last couple of months, indicating increasing interest in the company. Additionally, the company has 17,000 Twitter followers, though this has remained stable without any significant increase or decrease.

Finally, Alnylam Pharmaceuticals has received an AI score of 78 from AltIndex, which aggregates fundamental, technical, and alternative data analysis. This score indicates a buy signal.

Conclusion and Recommendation

Alnylam Pharmaceuticals exhibits robust revenue growth and increased market interest, as evidenced by its rising web traffic and social media engagement. However, dwindling net income and year-over-year EBITDA declines pose significant risks. While technical indicators suggest a potential downward trend in stock price, the overall alternative data analysis, including AI scores, presents a mixed yet fairly optimistic investment case.

Given the comprehensive analysis, a cautious approach is recommended. Investors should consider the positive growth indicators but remain wary of profitability concerns and insider selling. Continuous monitoring of financial performance and further market conditions is advisable before making substantial investment decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.